@phdthesis{Aido2024,
  author    = {Aido, Ahmed},
  title     = {Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)},
  doi       = {10.25972/OPUS-34921},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-349212},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Gold nanoparticles of diameter ca. 60 nm have been synthesized based on Turkevich and Frens protocols. We have demonstrated that the carboxyl-modified gold nanoparticles can be coupled covalently with antibodies (Ab) of interest using the EDC/NHS coupling procedure. Binding studies with Ab-grafted AuNPs and GpL fusion proteins proved that conjugation of AuNPs with antibodies enables immobilization of antibodies with preservation of a significant antigen binding capacity. More importantly, our findings showed that the conjugation of types of anti-TNF receptors antibodies such as anti-Fn14 antibodies (PDL192 and 5B6) (Aido et al., 2021), anti-CD40, anti-4-1BB and anti-TNFR2 with gold nanoparticles confers them with potent agonism. Thus, our results suggest that AuNPs can be utilized as a platform to immobilize anti-TNFR antibodies which, on the one hand, helps to enhance their agonistic activity in comparison to "free" inactive antibodies by mimicking the effect of cell-anchored antibodies or membrane-bound TNF ligands and, on the other hand, allows to develop new generations of drug delivery systems. These constructs are characterized with their biocompatibility and their tunable synthesis process. In a further work part, we combined the benefits of the established system of Ab-AuNPs with materials used widely in the modern biofabrication approaches such as the photo-crosslinked hydrogels, methacrylate-modified gelatin (GelMA), combined with embedded variants of human cell lines. The acquired results demonstrated clearly that the attaching of proteins like antibodies to gold nanoparticles might reduce their release rate from the crosslinked hydrogels upon the very low diffusion of gold nanoparticles from the solid constructs to the surrounding medium yielding long-term local functioning proteins-attached particles. Moreover, our finding suggests that hydrogel-embedded AuNP-immobilized antibodies, e.g. anti-TNFα-AuNPs or anti-IL1-AuNPs enable local inhibitory functions, To sum up, our results demonstrate that AuNPs can act as a platform to attach anti-TNFR antibodies to enhance their agonistic activity by resembling the output of cell-anchoring or membrane bounding. Gold nanoparticles are considered, thus, as promising tool to develop the next generation of drug delivery systems, which may contribute to cancer therapy. On top of that, the embedding of anti-inflammatory-AuNPs in the biofabricated hydrogel presents new innovative strategy of the treatment of autoinflammatory diseases.},
  subject      = {Nanopartikel},
  language  = {en}
}
@phdthesis{Kouhestani2021,
  author    = {Kouhestani, Dina},
  title     = {Complementation of a bimolecular Antibody-Derivative within the context of the Immunological Synapse},
  doi       = {10.25972/OPUS-20466},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-204669},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2021},
  abstract  = {Cancer is a disease of uncontrolled cell proliferation and migration. Downregulation of antigen-presenting major histocompatibility complex (MHC) and co-stimulatory molecules are two of the most commonly used pathways by cancer cells to escape from immune surveillance. Therefore, many approaches have been developed for restoring the immune surveillance in cancer patients. One approach is to redirect the patient's own T cells for tumor cell destruction. For T cell function it is important to induce a durable and robust cytotoxic response against target cells and to generate memory T cells, after MHC-mediated recognition of foreign intracellular antigens presented on the surface of antigen presenting cells (APC). Because of these cytotoxic properties, T cell mediated immunotherapy has been established as an effective and durable anti-neoplastic treatment. Different T cell mediated therapies for cancer treatment exist. One of them is using bispecific antibody fragments, so called bi-sepcific T cell engagers (BiTEs), for retargeting of T cells against single antigen positive tumor cells. The BiTE antibodies have two antigen binding domains, one against a target on the target cell, the second against CD3 on the T cells, facilitating cell-to-cell interactions. However, suitable single tumor antigens are limited, which restricts this approach to very few tumor types. To overcome this limitation, we have developed T cell-engaging antibody derivatives, termed hemibodies. Hemibodies exist as two complementary polypeptide chains. Each consists of two specific domains. On one end there is a single-chain variable fragment (scFv) against a target protein and on the other end there is either the heavy chain variable domain (VH) or light chain variable domain (VL) of an anti-CD3 binding antibody. Only when both hemibodies bind their respective antigens on the same tumor cell, the complementary anti CD3 VH and VL domains become aligned and reconstitute the functional CD3 binding-domain to engage T cells. For targeting malignant cells of hematopoietic origin, we used hemibodies against CD45 and HLA-A2. They were expressed in CHO cells, then purified via Strep-tag. To get more insight into the hemibody mechanism of T cell mediated target cell killing, we analyzed the biochemical and functional properties of hemibodies in more detail. Our main finding indicates that VLαCD3-scFvαHLA-A2 and VHαCD3-scFvαCD45 hemibodies induce an atypical immunological synapse characterized by a co-localization of HLA-A2 and CD45 out of the target cell -T cell interface. Nevertheless, hemibodies induce a high caspase activity in target cells in a concentration-dependent manner at nanomolar concentrations in vitro. Looking at ZAP70, which is usually recruited from the cytoplasm to the CD3 receptor in the middle of the cell-cell interface, we were able to detect activated ZAP70 outside of the cell-cell interface in the presence of hemibodies. In contrast cells treated with BiTEs show a central recruitment in the cell-cell interface as expected. We looked also at the interaction of hemibodies with soluble recombinant CD3 epsilon/gamma protein in the absence of target cells. The binding could be measured only at very high concentration out of the therapeutic window. This work contributes to the mechanistic understanding, which underlies the hemibody technology as a new dual antigen restricted T cell-mediated immunotherapy of cancer.},
  language  = {en}
}
@phdthesis{Kaiser2012,
  author    = {Kaiser, Fabian Marc Philipp},
  title     = {Analysis of Cross-Clade Neutralizing Antibodies against HIV-1 Env Induced by Immunofocusing},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-75494},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2012},
  abstract  = {Despite intense research efforts, a safe and effective HIV-1/AIDS vaccine still remains far away. HIV-1 escapes the humoral immune response through various mechanisms and until now, only a few nAbs have been identified. A promising strategy to identify new epitopes that may elicit such nAbs is to dissect and analyze the humoral immune response of sera with broadly reactive nAbs. The identified epitopes recognized by these antibodies might then be incorporated into a vaccine to elicit similar nAbs and thus provide protection from HIV-1 infection. Using random peptide phage display libraries, the Ruprecht laboratory has identified the epitopes recognized by polyclonal antibodies of a rhesus monkey with high-titer, broadly reactive nAbs that had been induced after infection with a SHIV encoding env of a recently transmitted HIV-1 clade C. The laboratory analyzed phage peptide inserts for conformational and linear homology with computational assistance. Several of the identified peptides mimicked domains of the original HIV-1 clade Env, such as conformational V3 loop epitopes and the conserved linear region of the gp120 C-terminus. As part of this work, these mimotopes were analyzed for cross-reactivity with other sera obtained from rhesus monkeys with nAbs and antibody recognition was shown for several mimotopes, particularly those representing the V3 loop. In addition, these mimotopes were incorporated into a novel DNA prime/phage boost strategy to analyze the immunogenicity of such phage-displayed peptides. Mice were primed only once with HIV-1 clade C gp160 DNA and subsequently boosted with mixtures of recombinant phages. This strategy was designed to focus the humoral immune response on a few, selected Env epitopes (immunofocusing) and induced HIV-1 clade C gp160 binding antibodies and cross-clade nAbs. Furthermore, the C-terminus of gp120, a conserved HIV Env region, was linked to the induction of nAbs for the first time. The identification of such conserved antigens may lead to the development of a vaccine that is capable of inducing broadly reactive nAbs that might confer protection form HIV-1 infection.},
  subject      = {Antik{\"o}rper},
  language  = {en}
}